ID SK-OV-3 AC CVCL_0532 SY SKOV-3; SK-OV3; SK.OV.3; SKOV3; Skov3; SKO3; SKOV3 (S) DR BTO; BTO_0000948 DR CLO; CLO_0009063 DR EFO; EFO_0002340 DR MCCL; MCC:0000431 DR CLDB; cl4354 DR CLDB; cl4355 DR CLDB; cl4356 DR AddexBio; C0017008/5024 DR ArrayExpress; E-MTAB-38 DR ArrayExpress; E-MTAB-783 DR ArrayExpress; E-MTAB-2706 DR ArrayExpress; E-MTAB-2770 DR ArrayExpress; E-MTAB-3610 DR ATCC; HTB-77 DR BCRJ; 0409 DR BioGRID_ORCS_Cell_line; 372 DR BioSample; SAMN03471310 DR BioSample; SAMN05292466 DR BioSample; SAMN10987874 DR cancercelllines; CVCL_0532 DR CancerTools; 161938 DR CCRID; 1101HUM-PUMC000027 DR CCRID; 3101HUMTCHu185 DR CCRID; 4201HUM-CCTCC00114 DR CCTCC; GDC0114 DR Cell_Model_Passport; SIDM00079 DR ChEMBL-Cells; CHEMBL3307746 DR ChEMBL-Targets; CHEMBL614925 DR CLS; 300342 DR Cosmic; 687925 DR Cosmic; 688110 DR Cosmic; 755846 DR Cosmic; 809115 DR Cosmic; 844348 DR Cosmic; 849611 DR Cosmic; 875858 DR Cosmic; 897436 DR Cosmic; 897739 DR Cosmic; 905959 DR Cosmic; 906578 DR Cosmic; 920359 DR Cosmic; 923106 DR Cosmic; 924150 DR Cosmic; 927563 DR Cosmic; 932983 DR Cosmic; 947358 DR Cosmic; 948289 DR Cosmic; 949228 DR Cosmic; 991320 DR Cosmic; 1044243 DR Cosmic; 1057759 DR Cosmic; 1066218 DR Cosmic; 1070900 DR Cosmic; 1071897 DR Cosmic; 1092635 DR Cosmic; 1093556 DR Cosmic; 1102817 DR Cosmic; 1113276 DR Cosmic; 1129658 DR Cosmic; 1139226 DR Cosmic; 1175886 DR Cosmic; 1176622 DR Cosmic; 1305333 DR Cosmic; 1312193 DR Cosmic; 1312359 DR Cosmic; 1436037 DR Cosmic; 1482526 DR Cosmic; 1523762 DR Cosmic; 1524361 DR Cosmic; 1707561 DR Cosmic; 1708388 DR Cosmic; 1709249 DR Cosmic; 1998478 DR Cosmic; 2301586 DR Cosmic; 2464670 DR Cosmic; 2560252 DR Cosmic; 2582807 DR Cosmic; 2668296 DR Cosmic-CLP; 905959 DR DepMap; ACH-000811 DR ECACC; 91091004 DR EGA; EGAS00001000610 DR EGA; EGAS00001000978 DR GDSC; 905959 DR GEO; GSM2110 DR GEO; GSM50223 DR GEO; GSM50287 DR GEO; GSM183338 DR GEO; GSM183341 DR GEO; GSM274701 DR GEO; GSM313702 DR GEO; GSM459638 DR GEO; GSM459643 DR GEO; GSM459644 DR GEO; GSM459645 DR GEO; GSM659405 DR GEO; GSM711713 DR GEO; GSM743478 DR GEO; GSM743500 DR GEO; GSM750833 DR GEO; GSM784565 DR GEO; GSM799368 DR GEO; GSM799431 DR GEO; GSM827322 DR GEO; GSM847159 DR GEO; GSM851940 DR GEO; GSM887598 DR GEO; GSM888681 DR GEO; GSM1001423 DR GEO; GSM1001424 DR GEO; GSM1001486 DR GEO; GSM1153439 DR GEO; GSM1181272 DR GEO; GSM1181301 DR GEO; GSM1291150 DR GEO; GSM1340593 DR GEO; GSM1374883 DR GEO; GSM1670455 DR GEO; GSM2124684 DR GEO; GSM2475005 DR IARC_TP53; 21123 DR ICLC; HTL01014 DR IGRhCellID; SKOV3 DR IZSLER; BS TCL 84 DR KCB; KCB 200810YJ DR KCLB; 30077 DR LiGeA; CCLE_824 DR LINCS_HMS; 50044 DR LINCS_LDP; LCL-1517 DR Lonza; 133 DR NCBI_Iran; C209 DR NCI-DTP; SK-OV-3 DR PharmacoDB; SKOV3_1411_2019 DR PRIDE; PXD001402 DR PRIDE; PXD005940 DR PRIDE; PXD005942 DR PRIDE; PXD005946 DR PRIDE; PXD007615 DR PRIDE; PXD030304 DR Progenetix; CVCL_0532 DR PubChem_Cell_line; CVCL_0532 DR SKY/M-FISH/CGH; 1438 DR Wikidata; Q50432263 RX PubMed=327080; RX PubMed=833871; RX PubMed=1423261; RX PubMed=1892748; RX PubMed=2041050; RX PubMed=2653399; RX PubMed=3335022; RX PubMed=3518877; RX PubMed=3804493; RX PubMed=4016745; RX PubMed=6582512; RX PubMed=7459858; RX PubMed=7718330; RX PubMed=8557231; RX PubMed=9041185; RX PubMed=9331090; RX PubMed=9554442; RX PubMed=9698466; RX PubMed=10318951; RX PubMed=10700174; RX PubMed=10972993; RX PubMed=11416159; RX PubMed=11565033; RX PubMed=11789735; RX PubMed=11793438; RX PubMed=12080474; RX PubMed=12417041; RX PubMed=12960427; RX PubMed=15748285; RX PubMed=16380993; RX PubMed=17088437; RX PubMed=17726699; RX PubMed=19372543; RX PubMed=20164919; RX PubMed=20204287; RX PubMed=20215515; RX PubMed=21912889; RX PubMed=22068913; RX PubMed=22328975; RX PubMed=22336246; RX PubMed=22347499; RX PubMed=22384151; RX PubMed=22460905; RX PubMed=22585861; RX PubMed=22628656; RX PubMed=22705003; RX PubMed=22710073; RX PubMed=23415752; RX PubMed=23839242; RX PubMed=23856246; RX PubMed=23933261; RX PubMed=24023729; RX PubMed=24279929; RX PubMed=24434149; RX PubMed=24670534; RX PubMed=25230021; RX PubMed=25485619; RX PubMed=25846456; RX PubMed=25877200; RX PubMed=25984343; RX PubMed=26169745; RX PubMed=26589293; RX PubMed=26668597; RX PubMed=26925792; RX PubMed=27235858; RX PubMed=27377824; RX PubMed=27397505; RX PubMed=27807467; RX PubMed=28196595; RX PubMed=28273451; RX PubMed=30485824; RX PubMed=30894373; RX PubMed=31068700; RX PubMed=32612269; RX PubMed=33519462; RX PubMed=35839778; RX PubMed=38861359; WW Info; MCLP; -; https://tcpaportal.org/mclp/ WW Info; NCI DTP; NCI-60; https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm WW Info; StRAP; -; https://strap.nci.nih.gov/celline_detail.php?sample_id=27 WW Info; Synapse; PS-ON; https://www.synapse.org/#!Synapse:syn31544449 WW Info; Thermo Fisher; -; https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/s/cell-lines-detail-19.html WW Info; Wikipedia; -; https://en.wikipedia.org/wiki/SK-OV-3 WW Provider; Altogen; Xenograft model; https://altogenlabs.com/xenograft-models/ovarian-cancer-xenograft/sk-ov-3-xenograft-model/ WW Provider; BRICS; BRICS0100; http://www.brics.ac.cn/cell/template/cell/cell_detail.html?id=3906 WW Provider; MSKCC; -; https://www.mskcc.org/research-advantage/support/technology/tangible-material/human-ovarian-cell-line-sk-ov-3 CC Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE). CC Part of: COSMIC cell lines project. CC Part of: JFCR39 cancer cell line panel. CC Part of: KuDOS 95 cell line panel. CC Part of: MD Anderson Cell Lines Project. CC Part of: NCI-60 cancer cell line panel. CC Part of: OCCP ovarian cancer cell line panel. CC From: Memorial Sloan Kettering Cancer Center; New York; USA. CC Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK1980-528. CC Population: Caucasian. CC Doubling time: 44 hours (PubMed=7718330); 19 hours (PubMed=2653399); 28 +- 2 hours (PubMed=3804493); 28.8 hours (PubMed=4016745); 75 hours (PubMed=25984343); 48.7 hours (NCI-DTP=SK-OV-3); ~35 hours (PBCF); 33.29 hours (JWGray panel). CC HLA typing: A*03,68; B*18,35; C*04,05; DPB1*02:01:02,04:01; DQB1*02:01,05:01:01; DRB1*01,03:01:01 (PubMed=15748285). CC HLA typing: A*03:01,68:01; B*18:01,35:01; C*04:01,05:01 (PubMed=26589293). CC Microsatellite instability: Instable (MSI-high) (PubMed=31068700; Sanger). CC Sequence variation: Mutation; HGNC; HGNC:583; APC; Simple; p.Thr1556Leufs*9 (c.4666delA); ClinVar=VCV000156477; Zygosity=Heterozygous (PubMed=17088437). CC Sequence variation: Mutation; HGNC; HGNC:16712; FBXW7; Simple; p.Arg505Leu (c.1514G>T); ClinVar=VCV000376424; Zygosity=Heterozygous (PubMed=11565033; PubMed=25846456). CC Sequence variation: Mutation; HGNC; HGNC:8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (PubMed=17088437; PubMed=22705003; PubMed=25846456; PubMed=28273451). CC Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Ser90Profs*33 (c.267delC); ClinVar=VCV000156515; Zygosity=Homozygous (PubMed=17088437; PubMed=20204287). CC Omics: Genomics; DNA methylation analysis. CC Omics: Genomics; Whole exome sequencing. CC Omics: Genomics; Whole genome sequencing. CC Omics: Metabolomics. CC Omics: Phenotyping; Drug screening. CC Omics: Phenotyping; Fluorescent probe library screening. CC Omics: Phenotyping; shRNA library screening. CC Omics: Proteomics. CC Omics: Proteomics; Expression; Reverse-phase protein array. CC Omics: Proteomics; Quantitative. CC Omics: Proteomics; Subcellular; Exosome. CC Omics: Transcriptomics; lncRNA profiling; RT-qPCR platform. CC Omics: Transcriptomics; Microarray. CC Omics: Transcriptomics; RNAseq. CC Omics: Variations; Array-based CGH. CC Omics: Variations; CNV analysis. CC Omics: Variations; SNP array analysis. CC Genome ancestry: African=1.52%; Native American=0%; East Asian, North=1.76%; East Asian, South=0%; South Asian=1.14%; European, North=59.05%; European, South=36.53% (PubMed=30894373). CC Misspelling: SCOV-3; Note=Occasionally. CC Misspelling: SCOV3; Note=Occasionally. CC Misspelling: SKVO3; Note=Occasionally. CC Discontinued: ICLC; HTL01014; true. CC Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795. ST Source(s): AddexBio=C0017008/5024; ATCC=HTB-77; CCRID; CLS=300342; Cosmic-CLP=905959; ECACC=91091004; KCLB=30077; PubMed=11416159; PubMed=19372543; PubMed=25230021; PubMed=25877200; PubMed=30485824; Technion Genomics Center ST Amelogenin: X ST CSF1PO: 11 ST D10S1248: 13,16,17 ST D12S391: 21,22 ST D13S317: 8,11 ST D16S539: 12 ST D18S51: 16,17 (ATCC=HTB-77; ECACC=91091004; PubMed=19372543; PubMed=25877200) ST D18S51: 16,17,18 (CCRID; CLS=300342; PubMed=11416159; Technion Genomics Center) ST D18S51: 16,18 (PubMed=25230021) ST D19S433: 14,14.2 ST D1S1656: 11,17.3 ST D21S11: 30,31,31.2 (CLS=300342; PubMed=11416159; PubMed=30485824) ST D21S11: 30,31.2 (ATCC=HTB-77; CCRID; PubMed=19372543; PubMed=25230021; PubMed=25877200; Technion Genomics Center) ST D22S1045: 11,16 ST D2S1338: 18,23 ST D2S441: 10,11.3 ST D3S1358: 13,14 (PubMed=19372543) ST D3S1358: 14 (ATCC=HTB-77; CCRID; CLS=300342; PubMed=25230021; PubMed=25877200; Technion Genomics Center) ST D5S818: 11 ST D7S820: 13,14 ST D8S1179: 14,15 ST FGA: 23,24,25 (ATCC=HTB-77; ECACC=91091004; Technion Genomics Center) ST FGA: 24,25 (CCRID; KCLB=30077; PubMed=25230021; PubMed=25877200) ST FGA: 24,25,26 (CLS=300342; PubMed=11416159) ST Penta D: 12,13 ST Penta E: 5,13 ST TH01: 9,9.3 ST TPOX: 8,11 ST vWA: 17 (PubMed=25230021) ST vWA: 17,18 (AddexBio=C0017008/5024; ATCC=HTB-77; CCRID; CLS=300342; Cosmic-CLP=905959; ECACC=91091004; KCLB=30077; PubMed=11416159; PubMed=25877200; PubMed=30485824; Technion Genomics Center) ST vWA: 18 (PubMed=19372543) DI NCIt; C7978; Ovarian serous cystadenocarcinoma OX NCBI_TaxID=9606; ! Homo sapiens (Human) SX Female AG 64Y CA Cancer cell line DT Created: 04-04-12; Last updated: 10-04-25; Version: 49 // RX PubMed=327080; DOI=10.1093/jnci/59.1.221; RA Fogh J., Fogh J.M., Orfeo T.; RT "One hundred and twenty-seven cultured human tumor cell lines RT producing tumors in nude mice."; RL J. Natl. Cancer Inst. 59:221-226(1977). // RX PubMed=833871; DOI=10.1093/jnci/58.2.209; RA Fogh J., Wright W.C., Loveless J.D.; RT "Absence of HeLa cell contamination in 169 cell lines derived from RT human tumors."; RL J. Natl. Cancer Inst. 58:209-214(1977). // RX PubMed=1423261; RA Mistry P., Kelland L.R., Loh S.Y., Abel G., Murrer B.A., Harrap K.R.; RT "Comparison of cellular accumulation and cytotoxicity of cisplatin RT with that of tetraplatin and RT amminedibutyratodichloro(cyclohexylamine)platinum(IV) (JM221) in human RT ovarian carcinoma cell lines."; RL Cancer Res. 52:6188-6193(1992). // RX PubMed=1892748; DOI=10.1038/bjc.1991.279; PMCID=PMC1977519; RA Mistry P., Kelland L.R., Abel G., Sidhar S., Harrap K.R.; RT "The relationships between glutathione, glutathione-S-transferase and RT cytotoxicity of platinum drugs and melphalan in eight human ovarian RT carcinoma cell lines."; RL Br. J. Cancer 64:215-220(1991). // RX PubMed=2041050; DOI=10.1093/jnci/83.11.757; RA Monks A., Scudiero D.A., Skehan P., Shoemaker R.H., Paull K.D., RA Vistica D.T., Hose C.D., Langley J., Cronise P., Vaigro-Wolff A., RA Gray-Goodrich M., Campbell H., Mayo J.G., Boyd M.R.; RT "Feasibility of a high-flux anticancer drug screen using a diverse RT panel of cultured human tumor cell lines."; RL J. Natl. Cancer Inst. 83:757-766(1991). // RX PubMed=2653399; DOI=10.1038/bjc.1989.108; PMCID=PMC2247140; RA Hills C.A., Kelland L.R., Abel G., Siracky J., Wilson A.P., RA Harrap K.R.; RT "Biological properties of ten human ovarian carcinoma cell lines: RT calibration in vitro against four platinum complexes."; RL Br. J. Cancer 59:527-534(1989). // RX PubMed=3335022; RA Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., RA Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.; RT "Feasibility of drug screening with panels of human tumor cell lines RT using a microculture tetrazolium assay."; RL Cancer Res. 48:589-601(1988). // RX PubMed=3518877; DOI=10.3109/07357908609038260; RA Fogh J.; RT "Human tumor lines for cancer research."; RL Cancer Invest. 4:157-184(1986). // RX PubMed=3804493; DOI=10.1002/ijc.2910390216; RA Hill B.T., Whelan R.D.H., Gibby E.M., Sheer D., Hosking L.K., RA Shellard S.A., Rupniak H.T.; RT "Establishment and characterisation of three new human ovarian RT carcinoma cell lines and initial evaluation of their potential in RT experimental chemotherapy studies."; RL Int. J. Cancer 39:219-225(1987). // RX PubMed=4016745; RA Buick R.N., Pullano R., Trent J.M.; RT "Comparative properties of five human ovarian adenocarcinoma cell RT lines."; RL Cancer Res. 45:3668-3676(1985). // RX PubMed=6582512; DOI=10.1073/pnas.81.2.568; PMCID=PMC344720; RA Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.; RT "Cell surface antigens of human ovarian and endometrial carcinoma RT defined by mouse monoclonal antibodies."; RL Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984). // RX PubMed=7459858; RA Rousset M., Zweibaum A., Fogh J.; RT "Presence of glycogen and growth-related variations in 58 cultured RT human tumor cell lines of various tissue origins."; RL Cancer Res. 41:1165-1170(1981). // RX PubMed=7718330; DOI=10.1016/0959-8049(94)00472-H; RA Baguley B.C., Marshall E.S., Whittaker J.R., Dotchin M.C., Nixon J., RA McCrystal M.R., Finlay G.J., Matthews J.H.L., Holdaway K.M., RA van Zijl P.L.; RT "Resistance mechanisms determining the in vitro sensitivity to RT paclitaxel of tumour cells cultured from patients with ovarian RT cancer."; RL Eur. J. Cancer 31A:230-237(1995). // RX PubMed=8557231; DOI=10.1006/gyno.1996.0014; RA Skilling J.S., Squatrito R.C., Connor J.P., Niemann T., Buller R.E.; RT "p53 gene mutation analysis and antisense-mediated growth inhibition RT of human ovarian carcinoma cell lines."; RL Gynecol. Oncol. 60:72-80(1996). // RX PubMed=9041185; RA Johnson S.W., Laub P.B., Beesley J.S., Ozols R.F., Hamilton T.C.; RT "Increased platinum-DNA damage tolerance is associated with cisplatin RT resistance and cross-resistance to various chemotherapeutic agents in RT unrelated human ovarian cancer cell lines."; RL Cancer Res. 57:850-856(1997). // RX PubMed=9331090; RA O'Connor P.M., Jackman J., Bae I., Myers T.G., Fan S.-J., Mutoh M., RA Scudiero D.A., Monks A., Sausville E.A., Weinstein J.N., Friend S.H., RA Fornace A.J. Jr., Kohn K.W.; RT "Characterization of the p53 tumor suppressor pathway in cell lines of RT the National Cancer Institute anticancer drug screen and correlations RT with the growth-inhibitory potency of 123 anticancer agents."; RL Cancer Res. 57:4285-4300(1997). // RX PubMed=9554442; DOI=10.1093/jnci/90.8.597; RA Sabichi A.L., Hendricks D.T., Bober M.A., Birrer M.J.; RT "Retinoic acid receptor beta expression and growth inhibition of RT gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) RT retinamide."; RL J. Natl. Cancer Inst. 90:597-605(1998). // RX PubMed=9698466; DOI=10.1006/gyno.1998.5039; RA Maxwell G.L., Risinger J.I., Tong B., Shaw H., Barrett J.C., RA Berchuck A., Futreal P.A.; RT "Mutation of the PTEN tumor suppressor gene is not a feature of RT ovarian cancers."; RL Gynecol. Oncol. 70:13-16(1998). // RX PubMed=10318951; DOI=10.1073/pnas.96.10.5722; PMCID=PMC21927; RA Lau K.-M., Mok S.C., Ho S.-M.; RT "Expression of human estrogen receptor-alpha and -beta, progesterone RT receptor, and androgen receptor mRNA in normal and malignant ovarian RT epithelial cells."; RL Proc. Natl. Acad. Sci. U.S.A. 96:5722-5727(1999). // RX PubMed=10700174; DOI=10.1038/73432; RA Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T., RA Iyer V.R., Jeffrey S.S., van de Rijn M., Waltham M.C., Pergamenschikov A., RA Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., RA Botstein D., Brown P.O.; RT "Systematic variation in gene expression patterns in human cancer cell RT lines."; RL Nat. Genet. 24:227-235(2000). // RX PubMed=10972993; DOI=10.1002/1098-2744(200008)28:4<236::AID-MC6>3.0.CO;2-H; RA Rauh-Adelmann C., Lau K.-M., Sabeti N., Long J.P., Mok S.C., Ho S.-M.; RT "Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon RT 12 deletion variant in malignant human ovarian, prostate, and breast RT cancer cell lines."; RL Mol. Carcinog. 28:236-246(2000). // RX PubMed=11416159; DOI=10.1073/pnas.121616198; PMCID=PMC35459; RA Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G., RA Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R., RA Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.; RT "Short tandem repeat profiling provides an international reference RT standard for human cell lines."; RL Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001). // RX PubMed=11565033; DOI=10.1038/35095068; RA Moberg K.H., Bell D.W., Pronk-Wahrer D.C.R., Haber D.A., Hariharan I.K.; RT "Archipelago regulates cyclin E levels in Drosophila and is mutated in RT human cancer cell lines."; RL Nature 413:311-316(2001). // RX PubMed=11789735; DOI=10.1309/4NCM-QJ9W-QM0J-6QJE; RA Rhodes A., Jasani B., Couturier J., McKinley M.J., Morgan J.M., RA Dodson A.R., Navabi H., Miller K.D., Balaton A.J.; RT "A formalin-fixed, paraffin-processed cell line standard for quality RT control of immunohistochemical assay of HER-2/neu expression in breast RT cancer."; RL Am. J. Clin. Pathol. 117:81-89(2002). // RX PubMed=11793438; DOI=10.1002/gcc.1221; RA Rao P.H., Harris C.P., Lu X.-Y., Li X.-N., Mok S.C., Lau C.C.; RT "Multicolor spectral karyotyping of serous ovarian adenocarcinoma."; RL Genes Chromosomes Cancer 33:123-132(2002). // RX PubMed=12080474; DOI=10.1038/sj.onc.1205542; RA Manzano R.G., Montuenga L.M., Dayton M.A., Dent P., Kinoshita I., RA Vicent S., Gardner G.J., Nguyen P., Choi Y.-H., Trepel J.B., RA Auersperg N., Birrer M.J.; RT "CL100 expression is down-regulated in advanced epithelial ovarian RT cancer and its re-expression decreases its malignant potential."; RL Oncogene 21:4435-4447(2002). // RX PubMed=12417041; DOI=10.1111/j.1349-7006.2002.tb01213.x; PMCID=PMC5926887; RA Watanabe T., Imoto I., Katahira T., Hirasawa A., Ishiwata I., Emi M., RA Takayama M., Sato A., Inazawa J.; RT "Differentially regulated genes as putative targets of amplifications RT at 20q in ovarian cancers."; RL Jpn. J. Cancer Res. 93:1114-1122(2002). // RX PubMed=12960427; DOI=10.1091/mbc.E03-05-0279; PMCID=PMC266758; RA Schaner M.E., Ross D.T., Ciaravino G., Sorlie T., Troyanskaya O.G., RA Diehn M., Wang Y.C., Duran G.E., Sikic T.L., Caldeira S., Skomedal H., RA Tu I.-P., Hernandez-Boussard T., Johnson S.W., O'Dwyer P.J., Fero M.J., RA Kristensen G.B., Borresen-Dale A.-L., Hastie T.J., Tibshirani R., RA van de Rijn M., Teng N.N.H., Longacre T.A., Botstein D., Brown P.O., RA Sikic B.I.; RT "Gene expression patterns in ovarian carcinomas."; RL Mol. Biol. Cell 14:4376-4386(2003). // RX PubMed=15748285; DOI=10.1186/1479-5876-3-11; PMCID=PMC555742; RA Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L., RA Morse H.C. 3rd, Stroncek D., Marincola F.M.; RT "HLA class I and II genotype of the NCI-60 cell lines."; RL J. Transl. Med. 3:11.1-11.8(2005). // RX PubMed=16380993; DOI=10.1002/ijc.21671; RA Huang K.-C., Park D.C., Ng S.-K., Lee J.Y., Ni X.-Y., Ng W.-C., RA Bandera C.A., Welch W.R., Berkowitz R.S., Mok S.C., Ng S.-W.; RT "Selenium binding protein 1 in ovarian cancer."; RL Int. J. Cancer 118:2433-2440(2006). // RX PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433; PMCID=PMC2705832; RA Ikediobi O.N., Davies H.R., Bignell G.R., Edkins S., Stevens C., RA O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L., RA Buck G., Butler A.P., Clements J., Cole J., Dicks E., Forbes S., RA Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C., RA Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A., RA Mironenko T., Parker A., Perry J., Raine K.M., Richardson D., RA Shepherd R., Small A., Smith R., Solomon H., Stephens P.J., RA Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.; RT "Mutation analysis of 24 known cancer genes in the NCI-60 cell line RT set."; RL Mol. Cancer Ther. 5:2606-2612(2006). // RX PubMed=17726699; DOI=10.1002/gcc.20492; RA Buys T.P.H., Chari R., Lee E.H.-L., Zhang M., MacAulay C., Lam S., RA Lam W.L., Ling V.; RT "Genetic changes in the evolution of multidrug resistance for cultured RT human ovarian cancer cells."; RL Genes Chromosomes Cancer 46:1069-1079(2007). // RX PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921; PMCID=PMC4020356; RA Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y., RA Chanock S.J., Weinstein J.N.; RT "DNA fingerprinting of the NCI-60 cell line panel."; RL Mol. Cancer Ther. 8:713-724(2009). // RX PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113; RA Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., RA Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., RA Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., RA Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.; RT "Signatures of mutation and selection in the cancer genome."; RL Nature 463:893-898(2010). // RX PubMed=20204287; DOI=10.3892/or_00000728; PMCID=PMC2909445; RA Langland G.T., Yannone S.M., Langland R.A., Nakao A., Guan Y.-H., RA Long S.B.T., Vonguyen L., Chen D.J., Gray J.W., Chen F.-Q.; RT "Radiosensitivity profiles from a panel of ovarian cancer cell lines RT exhibiting genetic alterations in p53 and disparate DNA-dependent RT protein kinase activities."; RL Oncol. Rep. 23:1021-1026(2010). // RX PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662; RA Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., RA Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., RA Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., RA Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., RA Haber D.A.; RT "A genome-wide screen for microdeletions reveals disruption of RT polarity complex genes in diverse human cancers."; RL Cancer Res. 70:2158-2164(2010). // RX PubMed=21912889; DOI=10.1007/s10637-011-9744-z; RA Sutherland H.S., Hwang I.Y., Marshall E.S., Lindsay B.S., Denny W.A., RA Gilchrist C., Joseph W.R., Greenhalgh D., Richardson E., Kestell P., RA Ding A., Baguley B.C.; RT "Therapeutic reactivation of mutant p53 protein by quinazoline RT derivatives."; RL Invest. New Drugs 30:2035-2045(2012). // RX PubMed=22068913; DOI=10.1073/pnas.1111840108; PMCID=PMC3219108; RA Gillet J.-P., Calcagno A.M., Varma S., Marino M., Green L.J., RA Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V., RA Padmanabhan R., Davidson B., Ganapathi R., Sood A.K., Rueda B.R., RA Ambudkar S.V., Gottesman M.M.; RT "Redefining the relevance of established cancer cell lines to the RT study of mechanisms of clinical anti-cancer drug resistance."; RL Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011). // RX PubMed=22328975; DOI=10.1158/2159-8290.CD-11-0170; PMCID=PMC3274821; RA Hanrahan A.J., Schultz N., Westfal M.L., Sakr R.A., Giri D.D., RA Scarperi S., Janakiraman M., Olvera N., Stevens E.V., She Q.-B., RA Aghajanian C., King T.A., de Stanchina E., Spriggs D.R., Heguy A., RA Taylor B.S., Sander C., Rosen N., Levine D.A., Solit D.B.; RT "Genomic complexity and AKT dependence in serous ovarian cancer."; RL Cancer Discov. 2:56-67(2012). // RX PubMed=22336246; DOI=10.1016/j.bmc.2012.01.017; RA Kong D.-X., Yamori T.; RT "JFCR39, a panel of 39 human cancer cell lines, and its application in RT the discovery and development of anticancer drugs."; RL Bioorg. Med. Chem. 20:1947-1951(2012). // RX PubMed=22347499; DOI=10.1371/journal.pone.0031628; PMCID=PMC3276511; RA Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.; RT "Mass homozygotes accumulation in the NCI-60 cancer cell lines as RT compared to HapMap trios, and relation to fragile site location."; RL PLoS ONE 7:e31628.1-e31628.9(2012). // RX PubMed=22384151; DOI=10.1371/journal.pone.0032096; PMCID=PMC3285665; RA Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H., RA Yoon C.N., Chang Y.-T.; RT "Identification of cancer cell-line origins using fluorescence RT image-based phenomic screening."; RL PLoS ONE 7:e32096.1-e32096.8(2012). // RX PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027; RA Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., RA Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., RA Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., RA Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., RA Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., RA Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., RA Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., RA Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., RA Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., RA Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., RA Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.; RT "The Cancer Cell Line Encyclopedia enables predictive modelling of RT anticancer drug sensitivity."; RL Nature 483:603-607(2012). // RX PubMed=22585861; DOI=10.1158/2159-8290.CD-11-0224; PMCID=PMC5057396; RA Marcotte R., Brown K.R., Suarez Saiz F.J., Sayad A., Karamboulas K., RA Krzyzanowski P.M., Sircoulomb F., Medrano M., Fedyshyn Y., Koh J.L.-Y., RA van Dyk D., Fedyshyn B., Luhova M., Brito G.C., Vizeacoumar F.J., RA Vizeacoumar F.S., Datti A., Kasimer D., Buzina A., Mero P., RA Misquitta C., Normand J., Haider M., Ketela T., Wrana J.L., RA Rottapel R., Neel B.G., Moffat J.; RT "Essential gene profiles in breast, pancreatic, and ovarian cancer RT cells."; RL Cancer Discov. 2:172-189(2012). // RX PubMed=22628656; DOI=10.1126/science.1218595; PMCID=PMC3526189; RA Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L., RA Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.; RT "Metabolite profiling identifies a key role for glycine in rapid RT cancer cell proliferation."; RL Science 336:1040-1044(2012). // RX PubMed=22705003; DOI=10.1016/j.humpath.2012.03.011; RA Rahman M., Nakayama K., Rahman M.T., Nakayama N., Ishikawa M., RA Katagiri A., Iida K., Nakayama S., Otsuki Y., Shih I.-M., RA Miyazaki K.; RT "Clinicopathologic and biological analysis of PIK3CA mutation in RT ovarian clear cell carcinoma."; RL Hum. Pathol. 43:2197-2206(2012). // RX PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017; PMCID=PMC3432677; RA Korch C.T., Spillman M.A., Jackson T.A., Jacobsen B.M., Murphy S.K., RA Lessey B.A., Jordan V.C., Bradford A.P.; RT "DNA profiling analysis of endometrial and ovarian cell lines reveals RT misidentification, redundancy and contamination."; RL Gynecol. Oncol. 127:241-248(2012). // RX PubMed=23415752; DOI=10.1016/j.molonc.2012.12.007; PMCID=PMC4106023; RA Stordal B., Timms K., Farrelly A., Gallagher D., Busschots S., RA Renaud M., Thery J., Williams D., Potter J., Tran T., Korpanty G., RA Cremona M., Carey M.S., Li J., Li Y., Aslan O., O'Leary J.J., RA Mills G.B., Hennessy B.T.; RT "BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one RT functionally deleterious BRCA1 mutation."; RL Mol. Oncol. 7:567-579(2013). // RX PubMed=23839242; DOI=10.1038/ncomms3126; PMCID=PMC3715866; RA Domcke S., Sinha R., Levine D.A., Sander C., Schultz N.; RT "Evaluating cell lines as tumour models by comparison of genomic RT profiles."; RL Nat. Commun. 4:2126.1-2126.10(2013). // RX PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342; PMCID=PMC4893961; RA Abaan O.D., Polley E.C., Davis S.R., Zhu Y.-L.J., Bilke S., Walker R.L., RA Pineda M.A., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L., RA Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.; RT "The exomes of the NCI-60 panel: a genomic resource for cancer biology RT and systems pharmacology."; RL Cancer Res. 73:4372-4382(2013). // RX PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018; RA Moghaddas Gholami A., Hahne H., Wu Z.-X., Auer F.J., Meng C., RA Wilhelm M., Kuster B.; RT "Global proteome analysis of the NCI-60 cell line panel."; RL Cell Rep. 4:609-620(2013). // RX PubMed=24023729; DOI=10.1371/journal.pone.0072162; PMCID=PMC3762837; RA Anglesio M.S., Wiegand K.C., Melnyk N., Chow C., Salamanca C.M., RA Prentice L.M., Senz J., Yang W., Spillman M.A., Cochrane D.R., RA Shumansky K., Shah S.P., Kalloger S.E., Huntsman D.G.; RT "Type-specific cell line models for type-specific ovarian cancer RT research."; RL PLoS ONE 8:e72162.1-e72162.13(2013). // RX PubMed=24279929; DOI=10.1186/2049-3002-1-20; PMCID=PMC4178206; RA Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R., RA Hirshfield K.M., Oltvai Z.N., Vazquez A.; RT "The metabolic demands of cancer cells are coupled to their size and RT protein synthesis rates."; RL Cancer Metab. 1:20.1-20.13(2013). // RX PubMed=24434149; DOI=10.1016/j.bbrc.2013.12.070; RA Sinha A., Ignatchenko V., Ignatchenko A., Mejia-Guerrero S., RA Kislinger T.; RT "In-depth proteomic analyses of ovarian cancer cell line exosomes RT reveals differential enrichment of functional categories compared to RT the NCI 60 proteome."; RL Biochem. Biophys. Res. Commun. 445:694-701(2014). // RX PubMed=24670534; DOI=10.1371/journal.pone.0092047; PMCID=PMC3966786; RA Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.; RT "High resolution copy number variation data in the NCI-60 cancer cell RT lines from whole genome microarrays accessible through CellMiner."; RL PLoS ONE 9:e92047.1-e92047.15(2014). // RX PubMed=25230021; DOI=10.1371/journal.pone.0103988; PMCID=PMC4167545; RA Beaufort C.M., Helmijr J.C.A., Piskorz A.M., Hoogstraat M., RA Ruigrok-Ritstier K., Besselink N., Murtaza M., van IJcken W.F.J., RA Heine A.A.J., Smid M., Koudijs M.J., Brenton J.D., Berns E.M.J.J., RA Helleman J.; RT "Ovarian cancer cell line panel (OCCP): clinical importance of in RT vitro morphological subtypes."; RL PLoS ONE 9:e103988.1-e103988.16(2014). // RX PubMed=25485619; DOI=10.1038/nbt.3080; RA Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., RA Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., RA Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., RA Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., RA Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., RA Settleman J., Seshagiri S., Zhang Z.-M.; RT "A comprehensive transcriptional portrait of human cancer cell RT lines."; RL Nat. Biotechnol. 33:306-312(2015). // RX PubMed=25846456; DOI=10.3892/ijo.2015.2951; RA Takenaka M., Saito M., Iwakawa R., Yanaihara N., Saito M., Kato M., RA Ichikawa H., Shibata T., Yokota J., Okamoto A., Kohno T.; RT "Profiling of actionable gene alterations in ovarian cancer by RT targeted deep sequencing."; RL Int. J. Oncol. 46:2389-2398(2015). // RX PubMed=25877200; DOI=10.1038/nature14397; RA Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., RA Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., RA Neve R.M.; RT "A resource for cell line authentication, annotation and quality RT control."; RL Nature 520:307-311(2015). // RX PubMed=25984343; DOI=10.1038/sdata.2014.35; PMCID=PMC4432652; RA Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., RA East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., RA Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., RA Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S., RA Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D., RA Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C., RA Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., RA Golub T.R., Root D.E., Hahn W.C.; RT "Parallel genome-scale loss of function screens in 216 cancer cell RT lines for the identification of context-specific genetic RT dependencies."; RL Sci. Data 1:140035.1-140035.12(2014). // RX PubMed=26169745; DOI=10.1186/s12967-015-0576-z; PMCID=PMC4499939; RA Halama A., Guerrouahen B.S., Pasquier J., Diboun I., Karoly E.D., RA Suhre K., Rafii A.; RT "Metabolic signatures differentiate ovarian from colon cancer cell RT lines."; RL J. Transl. Med. 13:223.1-223.12(2015). // RX PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878; RA Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., RA Loewer M., Sahin U., Castle J.C.; RT "TCLP: an online cancer cell line catalogue integrating HLA type, RT predicted neo-epitopes, virus and gene expression."; RL Genome Med. 7:118.1-118.7(2015). // RX PubMed=26668597; DOI=10.3892/etm.2015.2836; PMCID=PMC4665172; RA Ruan Z.-Y., Liu J.-H., Kuang Y.-P.; RT "Isolation and characterization of side population cells from the RT human ovarian cancer cell line SK-OV-3."; RL Exp. Ther. Med. 10:2071-2078(2015). // RX PubMed=26925792; DOI=10.4149/315_150930N510; RA Saczko J., Pilat J., Choromanska A., Rembialkowska N., Bar J.K., RA Deszcz I., Zalewski J., Kulbacka J.; RT "The effectiveness of chemotherapy and electrochemotherapy on ovarian RT cell lines in vitro."; RL Neoplasma 63:450-455(2016). // RX PubMed=27235858; DOI=10.1016/j.ygyno.2016.05.028; PMCID=PMC4961516; RA Hernandez L., Kim M.K., Lyle L.T., Bunch K.P., House C.D., Ning F., RA Noonan A.M., Annunziata C.M.; RT "Characterization of ovarian cancer cell lines as in vivo models for RT preclinical studies."; RL Gynecol. Oncol. 142:332-340(2016). // RX PubMed=27377824; DOI=10.1038/sdata.2016.52; PMCID=PMC4932877; RA Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J., RA Vandesompele J.; RT "Long non-coding RNA expression profiling in the NCI60 cancer cell RT line panel using high-throughput RT-qPCR."; RL Sci. Data 3:160052.1-160052.6(2016). // RX PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469; RA Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., RA Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., RA Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., RA Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., RA Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., RA Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., RA Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., RA Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.; RT "A landscape of pharmacogenomic interactions in cancer."; RL Cell 166:740-754(2016). // RX PubMed=27807467; DOI=10.1186/s13100-016-0078-4; PMCID=PMC5087121; RA Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J., RA Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.; RT "A map of mobile DNA insertions in the NCI-60 human cancer cell RT panel."; RL Mob. DNA 7:20.1-20.11(2016). // RX PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076; RA Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., RA Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., RA Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., RA Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., RA Liang H.; RT "Characterization of human cancer cell lines by reverse-phase protein RT arrays."; RL Cancer Cell 31:225-239(2017). // RX PubMed=28273451; DOI=10.1016/j.celrep.2017.02.028; RA Medrano M., Communal L., Brown K.R., Iwanicki M., Normand J., RA Paterson J., Sircoulomb F., Krzyzanowski P.M., Novak M., Doodnauth S.A., RA Suarez Saiz F.J., Cullis J., Al-awar R., Neel B.G., McPherson J., RA Drapkin R.I., Ailles L., Mes-Masson A.-M., Rottapel R.; RT "Interrogation of functional cell-surface markers identifies CD151 RT dependency in high-grade serous ovarian cancer."; RL Cell Rep. 18:2343-2358(2017). // RX PubMed=30485824; DOI=10.1016/j.celrep.2018.10.096; PMCID=PMC6481945; RA Papp E., Hallberg D., Konecny G.E., Bruhm D.C., Adleff V., Noe M., RA Kagiampakis I., Palsgrove D., Conklin D., Kinose Y., White J.R., RA Press M.F., Drapkin R.I., Easwaran H., Baylin S.B., Slamon D.J., RA Velculescu V.E., Scharpf R.B.; RT "Integrated genomic, epigenomic, and expression analyses of ovarian RT cancer cell lines."; RL Cell Rep. 25:2617-2633(2018). // RX PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675; RA Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.; RT "An interactive resource to probe genetic diversity and estimated RT ancestry in cancer cell lines."; RL Cancer Res. 79:1263-1273(2019). // RX PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103; RA Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., RA McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., RA Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., RA Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., RA Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., RA Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., RA Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., RA Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., RA Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., RA Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., RA Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., RA Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., RA Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., RA Sellers W.R.; RT "Next-generation characterization of the Cancer Cell Line RT Encyclopedia."; RL Nature 569:503-508(2019). // RX PubMed=32612269; DOI=10.1038/s41598-020-67533-1; PMCID=PMC7329846; RA De Haven Brandon A.K., Box G., Hallsworth A., Court W., Matthews N., RA Herodek B., Arteagabeitia A.B., Valenti M., Kirkin V.; RT "Identification of ovarian high-grade serous carcinoma cell lines that RT show estrogen-sensitive growth as xenografts in immunocompromised RT mice."; RL Sci. Rep. 10:10799.1-10799.13(2020). // RX PubMed=33519462; DOI=10.3389/fphar.2020.600994; PMCID=PMC7838559; RA Zhang Y.-Q., Gan H.-Y., Zhao F., Ma X.-M., Xie X.-F., Huang R., Zhao J.; RT "CPEB4-promoted paclitaxel resistance in ovarian cancer in vitro RT relies on translational regulation of CSAG2."; RL Front. Pharmacol. 11:600994.1-600994.10(2020). // RX PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775; RA Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., RA Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., RA Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., RA Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., RA Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., RA Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.; RT "Pan-cancer proteomic map of 949 human cell lines."; RL Cancer Cell 40:835-849.e8(2022). // RX PubMed=38861359; DOI=10.1158/0008-5472.CAN-23-3031; PMCID=PMC11292194; RA Kunkel M.W., Coussens N.P., Morris J., Taylor R.C., Dexheimer T.S., RA Jones E.M., Doroshow J.H., Teicher B.A.; RT "HTS384 NCI60: the next phase of the NCI60 screen."; RL Cancer Res. 84:2403-2416(2024). //